RESUMO
BACKGROUND: Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria). In oncology, pruritus-associated cutaneous adverse events (paCAEs) are frequent with immune checkpoint inhibitors (CPIs) and targeted anti-human epidermal growth factor receptor 2 (HER2) therapies. Thus, we sought to evaluate the efficacy and safety of IgE blockade with omalizumab in cancer patients with refractory paCAEs related to CPIs and anti-HER2 agents. PATIENTS AND METHODS: Patients included in this multicenter retrospective analysis received monthly subcutaneous injections of omalizumab for CPI or anti-HER2 therapy-related grade 2/3 pruritus that was refractory to topical corticosteroids plus at least one additional systemic intervention. To assess clinical response to omalizumab, we used the Common Terminology Criteria for Adverse Events version 5.0. The primary endpoint was defined as reduction in the severity of paCAEs to grade 1/0. RESULTS: A total of 34 patients (50% female, median age 67.5 years) received omalizumab for cancer therapy-related paCAEs (71% CPIs; 29% anti-HER2). All had solid tumors (29% breast, 29% genitourinary, 15% lung, 26% other), and most (n = 18, 64%) presented with an urticarial phenotype. In total 28 of 34 (82%) patients responded to omalizumab. The proportion of patients receiving oral corticosteroids as supportive treatment for management of paCAEs decreased with IgE blockade, from 50% to 9% (P < 0.001). Ten of 32 (31%) patients had interruption of oncologic therapy due to skin toxicity; four of six (67%) were successfully rechallenged following omalizumab. There were no reports of anaphylaxis or hypersensitivity reactions related to omalizumab. CONCLUSIONS: IgE blockade with omalizumab demonstrated clinical efficacy and was well tolerated in cancer patients with pruritus related to CPIs and anti-HER2 therapies.
Assuntos
Imunoglobulina E , Omalizumab , Idoso , Feminino , Humanos , Inibidores de Checkpoint Imunológico , Masculino , Omalizumab/efeitos adversos , Prurido/induzido quimicamente , Prurido/tratamento farmacológico , Estudos RetrospectivosRESUMO
BACKGROUND: Dermatologic adverse events (dAEs) of anticancer therapies may negatively impact dosing and quality of life. While therapy interruption patterns due to dAEs have been studied in hospitalized cancer patients, similar outcomes in outpatient oncodermatology are lacking. OBJECTIVES: To analyse the therapy interruption patterns, clinico-histopathologic characteristics and management outcomes of outpatient dermatology consultations for acute dAEs attributed to the most frequently interrupted class of oncologic agents. METHODS: We performed a retrospective cohort study of all cancer patients who received a same-day outpatient dermatology consultation for acute dAEs at our institution from 1 January to 30 June 2015. Relevant data were abstracted from electronic medical records, including demographics, oncologic history and explicit recommendations by both the referring clinician and consulting dermatologist on anticancer therapy interruption. Consultations with the most frequently interrupted class of oncologic treatment were characterized according to clinico-histopathologic features, dermatologic management and clinical outcomes. RESULTS: There were 426 same-day outpatient dermatology consultations (median age 59, 60% female, 30% breast cancer), of which 295 (69%) had systemic anticancer therapy administered within 30 days prior. There was weak inter-rater agreement between referring clinicians and consulting dermatologists on interruption of anticancer treatment (n = 150, κ = 0.096; 95% CI -0.02 to 0.21). Seventy-three (25%) consultations involved interruption by the referring clinician, most commonly targeted therapy (24, 33%). Maculopapular rash was commonly observed in 23 consultations with 25 dAEs attributed to targeted agents (48%), and topical corticosteroids were most frequently utilized for management (22, 38%). The majority (83%) of consultations with targeted therapy-induced dAEs responded to dermatologic treatment and 84% resumed oncologic therapy, although three (19%) at a reduced dose. Rash recurred only in two instances (13%). CONCLUSIONS: A high frequency of positive outcomes in the management of targeted therapy-induced dAEs by outpatient consulting dermatologists and low recurrence of skin toxicity suggests impactful reductions in interruption of anticancer therapy.
Assuntos
Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Toxidermias/prevenção & controle , Neoplasias/tratamento farmacológico , Encaminhamento e Consulta , Dermatopatias Infecciosas/prevenção & controle , Adolescente , Corticosteroides/uso terapêutico , Adulto , Idoso , Alopecia/induzido quimicamente , Assistência Ambulatorial , Antineoplásicos Imunológicos/administração & dosagem , Antineoplásicos Imunológicos/efeitos adversos , Dermatologia , Toxidermias/tratamento farmacológico , Toxidermias/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças da Unha/induzido quimicamente , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/efeitos adversos , Estudos Retrospectivos , Dermatopatias Infecciosas/induzido quimicamenteRESUMO
BACKGROUND: The effect of a pulmonary embolism response team (PERT) in the short-term prognosis of patients with acute symptomatic pulmonary embolism (PE) lacks clarity. We therefore aimed at evaluating the effect of a PERT team on short-term mortality among patients with acute PE. METHODS: We retrospectively reviewed consecutive patients with acute symptomatic PE enrolled in a single-center registry between 2007 and 2022. We used propensity score matching to compare treatment effects for patients with similar predicted probabilities of receiving management by the PERT team. The primary outcome was all-cause mortality within 30 days following the diagnosis of PE. The secondary outcome was 30-day PE-related mortality. RESULTS: Of the 2,902 eligible patients who had acute symptomatic PE, 223 (7.7%; 95% confidence interval [CI], 6.7%-8.7%) were managed by the PERT team. Two hundred and seven patients who were treated by the PERT were matched with 207 patients who were not. Matched pairs did not show a statistically significant lower all-cause (odds ratio [OR], 1.09; 95% CI, 0.63-1.89) or PE-related death (OR, 1.30; 95% CI, 0.47-3.62) for PERT management compared with no PERT management through 30 days after diagnosis of PE. CONCLUSIONS: Our results suggest that multidisciplinary care of patients with acute symptomatic PE by a PERT team is not associated with a significant reduction in short-term all-cause or PE-related mortality.
Assuntos
Embolia Pulmonar , Humanos , Estudos Retrospectivos , Prognóstico , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/terapiaRESUMO
Zinc and boron are nutrients that often suffer low bioavailability to pecan trees grown in calcareous soils whereas adequate supplies of these two elements is essential for commercial pecan production. Working with young pecan trees, we evaluated changes in oxidative metabolism, levels of bioactive compounds, yield components and foliar nutrient concentrations in response to foliar sprays (50 or 100 mg L-1) of zinc oxide nanoparticles (ZnO NPs) and boron (H3BO3). Four different treatment solutions were applied in a completely randomised design with six replications per treatment (24 trees in total). Zinc and B treatments were applied before pistil receptivity (3 weeks before anthesis) and at stem elongation stage 31, 39/60; flowering stage 69; fruit stages 7-75 and continued for a total of five applications at 14-day intervals. We evaluated enzyme activities (SOD, H2O2, CAT and GPx), AC, phenols, flavonoids, leaf area, chlorophyll, total anthocyanins and nut yield and quality (nut weight and % kernel). The mineral concentrations in the leaflets were also determined. The mineral concentrations (N, P, K, Ca, Mg, Fe, Cu, Mn, Ni, Zn and B) in the leaflets were also determined. Spraying ZnO NPs and B increased SOD activity, CA, chlorophyll concentration, mineral nutrients (N, K, Ca, Zn and B) and yield. However, reductions were observed for CAT activity, nut quality and concentrations of phenol, flavonoid, anthocyanin and Fe. Boron increased GPx activity and P concentration. These results demonstrate that spraying low doses (50 mg L-1) of ZnO NPs and B can help reduce oxidative stress and increase yield, nut quality and leaf concentrations of Zn and B in young cv. Wichita pecan trees established on a calcareous soil.
RESUMO
BACKGROUND: Here, Leishmania presence in sand flies from Três Lagoas, Mato Grosso do Sul, Brazil, after visceral leishmaniasis (VL) was investigated. METHODS: In April 2022, two light traps were deployed within and around the residence for two days post-VL case report. RESULTS: A total of 120 Lutzomyia longipalpis were collected. Suprapyloric flagellates were found in a female sand fly with eggs and residual blood during midgut dissection. Sequencing of ITS1 and cytb fragments confirmed Leishmania infantum DNA and identified Homo sapiens as the blood source, respectively. CONCLUSIONS: This study emphasizes the importance of monitoring sand flies in VL endemic areas.
Assuntos
Leishmania infantum , Leishmaniose Visceral , Psychodidae , Animais , Feminino , Leishmaniose Visceral/epidemiologia , Leishmania infantum/genética , Brasil/epidemiologia , Incidência , Insetos VetoresRESUMO
Dog vaccination is considered an effective way of reducing Leishmania infantum infection incidence in the canine population, as well as its transmission to humans. However, the use of partially effective vaccines can have the detrimental effect of "masking" vaccinated asymptomatic carriers, capable of harbouring the parasite and transmitting it to naïve individuals. After eight years on the European market, few studies have been released on CaniLeish® vaccine safety and efficacy. The present study, a one-year randomized CaniLeish® vaccine field trial, was performed in a canine leishmaniosis endemic area and included animals selected from a native dog population (n = 168). No severe adverse reactions were observed in vaccinated dogs (n = 85). Cases of active L. infantum infection were detected by serological, molecular and clinical follow-up of dogs. One-year post-vaccination, no differences in number or severity of L. infantum active infections were observed between study groups (n = 4 in each group). Vaccine-induced cellular immunity, assessed through interferon-γ quantification, showed significantly higher levels of this cytokine one-month post-vaccination in the vaccine group (p < 0.001), but no differences were observed after nine months between trial groups (p = 0.078). These results fail to support the reported CaniLeish® efficacy in the prevention of active L. infantum infection in dogs from endemic areas and naturally exposed to the parasite.
Assuntos
Doenças do Cão/prevenção & controle , Leishmania infantum/imunologia , Vacinas contra Leishmaniose/imunologia , Leishmaniose Visceral/veterinária , Vacinação/veterinária , Animais , Doenças do Cão/epidemiologia , Cães , Feminino , Interferon gama/sangue , Vacinas contra Leishmaniose/efeitos adversos , Leishmaniose Visceral/epidemiologia , Leishmaniose Visceral/prevenção & controle , MasculinoRESUMO
Essentials Low-molecular-weight heparin (LMWH) injections for venous thromboembolism (VTE) may be burdensome. Patients with active cancer and confirmed VTE were included to evaluate LMWH continuation. The cumulative incidence of discontinuation was 21% after a median period of 90 days. One out of five patients discontinued LMWH injections because of side effects. SUMMARY: Background Current guidelines recommend low-molecular-weight heparin (LMWH) monotherapy for 3-6 months as the first-line treatment for cancer-associated venous thromboembolism (VTE). However, although daily administration of LMWH injections over a course of several months may be burdensome, the number of patients who stop treatment because of LMWH side-effects is unknown. Objectives To evaluate the continuation rate and complications of daily LMWH injections in patients with cancer-associated VTE. Methods Consecutive patients with active cancer and objectively confirmed symptomatic proximal deep vein thrombosis and/or pulmonary embolism, treated at three Dutch hospitals and one Spanish hospital, were included to evaluate continuation LMWH therapy during LMWH treatment. Patients were excluded when they received other anticoagulants, were lost to follow-up, or experienced a venous catheter-associated thrombosis. Results A total of 372 patients were analyzed during LMWH treatment for a maximum of 180 days. The cumulative incidence of discontinuation was 21% (95% confidence interval [CI] 17-25) after a median period of 90 days (interquartile range 60-120 days). Only female sex was found to be significantly associated with premature LMWH discontinuation (odds ratio 1.6; 95% CI 1.03-2.5). Thirty patients (8.1%) developed recurrent VTE, 30 patients (8.3%) suffered a major bleed, and 106 patients (28%) died. Conclusion Our study reveals that one of five patients with cancer-associated VTE stopped LMWH injections because of side-effects. This finding provides relevant background information for current clinical trials investigating the efficacy and safety of direct oral anticoagulants as compared with LMWH.
Assuntos
Heparina de Baixo Peso Molecular/uso terapêutico , Neoplasias/tratamento farmacológico , Tromboembolia Venosa/tratamento farmacológico , Idoso , Anticoagulantes/uso terapêutico , Catéteres/efeitos adversos , Feminino , Seguimentos , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Neoplasias/complicações , Razão de Chances , Estudos Prospectivos , Resultado do Tratamento , Tromboembolia Venosa/complicaçõesRESUMO
UNLABELLED: Essentials (NZWxBXSB)F1 male mice develop antibodies beta2-glycoprotein I (ß2GPI) and hypertension. A1-A1 is a soluble analogue of ApoE receptor 2 with a high affinity for ß2GPI/antibody complexes. A1-A1 improved blood pressure and arterial elastance in (NZWxBXSB)F1 male mice. A1-A1 had no adverse effects on the hemodynamics of healthy mice. SUMMARY: Background Antiphospholipid syndrome (APS) is diagnosed based on the presence of antiphospholipid antibodies and clinical thrombosis or fetal loss during pregnancy. Lupus-prone (NZWxBXSB)F1 male mice are the mouse model of spontaneous APS. They develop anti-ß2GPI antibodies, microinfarcts and hypertension. ApoER2 is a receptor that contributes to anti-ß2GPI-dependent thrombosis in APS by down-regulating endothelial nitric oxide synthase activation. Objectives A1-A1 is a small protein constructed from two identical ligand-binding modules from ApoER2, containing the binding site for ß2GPI. We studied how treatment with A1-A1 affects the development of hypertension in (NZWxBXSB)F1 male mice. Methods We treated (NZWxBXSB)F1 male mice with A1-A1 for up to 4 weeks and examined changes in hemodynamics by left ventricular pressure-volume loop measurements. Results We observed improvements in blood pressure in the A1-A1 treated mice. A1-A1 prevented the deterioration of arterial elastance by decreasing systemic resistance and improving vessel compliance. We did not detect any adverse effects of the treatment in either male mice or in apparently healthy female (NZWxBXSB)F1 mice. Conclusions We demonstrated that A1-A1, which is a soluble analog of ApoER2 that binds pathological ß2GPI/anti-ß2GPI complexes, has a positive impact on hemodynamics in lupus-prone mice with spontaneous anti-ß2GPI antibodies and hypertension.
Assuntos
Síndrome Antifosfolipídica/sangue , Proteínas Relacionadas a Receptor de LDL/sangue , Proteínas Relacionadas a Receptor de LDL/metabolismo , Nefrite Lúpica/imunologia , beta 2-Glicoproteína I/imunologia , Animais , Anticorpos Antifosfolipídeos/imunologia , Complexo Antígeno-Anticorpo , Síndrome Antifosfolipídica/imunologia , Pressão Sanguínea , Modelos Animais de Doenças , Elasticidade , Feminino , Hemodinâmica , Humanos , Hipertensão/metabolismo , Imunoglobulina G/sangue , Rim/metabolismo , Ligantes , Metabolismo dos Lipídeos , Nefrite Lúpica/sangue , Masculino , Camundongos , Camundongos Transgênicos , Óxido Nítrico Sintase Tipo III/metabolismo , Solubilidade , Trombose/patologiaRESUMO
Nine, Brucella abortus culture positive 2-yr-old cows were used to test the hypothesis that embryos and ova collected from such cows are not infected. Superovulation was induced at varying times postpartum or postabortion with intramuscular injections of follicle stimulating hormone (FSH). The cows were artificially inseminated with B. abortus-negative semen. Superovulations and nonsurgical embryo collections nonsurgical embryo collections were attempted twice for each cow. Jugular blood, udder secretions, cervical swabs, uterine collections, embryos and ova were cultured bacteriologically from the nine cows simultaneously at nonsurgical embryro collections, and B. abortus was isolated only from the udder secretions of seven cows. Brucella abortus was not isolated from 15 uterine collections, 21 embryos, or 18 ova from the culture-positive cows. It was concluded that B. abortus was not present at the detection limits of the culture method employed, which supports the finding or view that embryos and ova collected from donor cows at 100 days or greater post partum or post abortion are not likely to harbor Brucella.
RESUMO
Antecedentes No se han aclarado suficientemente los beneficios del manejo multidisciplinar (código TEP) de los pacientes con tromboembolia de pulmón (TEP) aguda sintomática. El objetivo de este estudio fue evaluar el efecto sobre la mortalidad a corto plazo del código TEP comparado con la atención habitual. Métodos Realizamos un estudio retrospectivo que incluyó a todos los pacientes con diagnóstico de TEP aguda sintomática ingresados en un hospital terciario universitario entre los años 2007 y 2022. Mediante un análisis de emparejamiento exacto 1:1, los pacientes atendidos por un equipo multidisciplinar para el manejo de la TEP (código TEP) fueron emparejados con otros que recibieron la atención habitual (es decir, no multidisciplinar) para la TEP. El evento primario de eficacia fue la mortalidad por cualquier causa durante los 30 primeros días después del diagnóstico. El evento secundario de eficacia fue la mortalidad por la propia TEP durante el mismo período de tiempo. Resultados De los 2.902 pacientes con diagnóstico de TEP aguda sintomática incluidos en este estudio, 223 (7,7%; intervalo de confianza [IC] del 95%: 6,7-8,7%) fueron manejados por el código TEP. Se emparejaron 207 pacientes manejados por el código TEP con 207 pacientes manejados de forma habitual. En la cohorte emparejada, la atención multidisciplinar a los pacientes con TEP aguda sintomática no se asoció a una reducción significativa de la mortalidad por cualquier causa (odds ratio [OR]: 1,09; IC del 95%: 0,63-1,89) o por la propia TEP (OR: 1,30; IC del 95%: 0,47-3,62) en el mes posterior al diagnóstico de la TEP. Conclusiones La atención multidisciplinar a los pacientes con TEP aguda sintomática no se asoció a una reducción significativa de la mortalidad precoz. (AU)
Background The effect of a pulmonary embolism response team (PERT) in the short-term prognosis of patients with acute symptomatic pulmonary embolism (PE) lacks clarity. We therefore aimed at evaluating the effect of a PERT team on short-term mortality among patients with acute PE. Methods We retrospectively reviewed consecutive patients with acute symptomatic PE enrolled in a single-center registry between 2007 and 2022. We used propensity score matching to compare treatment effects for patients with similar predicted probabilities of receiving management by the PERT team. The primary outcome was all-cause mortality within 30 days following the diagnosis of PE. The secondary outcome was 30-day PE-related mortality. Results Of the 2,902 eligible patients who had acute symptomatic PE, 223 (7.7%; 95% confidence interval [CI], 6.7%-8.7%) were managed by the PERT team. Two hundred and seven patients who were treated by the PERT were matched with 207 patients who were not. Matched pairs did not show a statistically significant lower all-cause (odds ratio [OR], 1.09; 95% CI, 0.63-1.89) or PE-related death (OR, 1.30; 95% CI, 0.47-3.62) for PERT management compared with no PERT management through 30 days after diagnosis of PE. Conclusions Our results suggest that multidisciplinary care of patients with acute symptomatic PE by a PERT team is not associated with a significant reduction in short-term all-cause or PE-related mortality. (AU)
Assuntos
Humanos , Embolia Pulmonar , Equipe de Assistência ao Paciente , Prognóstico , Estudos RetrospectivosRESUMO
RESUMEN En los últimos años el agronegocio porcino creció significativamente a nivel nacional y departamental; esta cadena productiva está conformada por proveedores de insumos, productores primarios, comercializadores, agroindustria, comercio mayorista, comercio minorista y consumidores. El presente estudio caracterizó los agentes del mercado que interactúan a lo largo de la cadena productiva y, además, cuantificó los márgenes de comercialización de la carne de cerdo en la subregión del Valle de Aburrá, departamento de Antioquia (Colombia). Para ello, se aplicó muestreo no probabilístico a conveniencia, adicionalmente, se aplicó una encuesta a 30 productores y entrevista semiestructurada a cinco agentes de mercadeo. Se encontraron dos circuitos de comercialización principales: productor-expendedor de carne y productor-intermediario-expendedor de carne. Los precios pagados a los agentes que interactúan en el circuito de la carne de cerdo en el Valle de Aburrá presentan tendencia al alza. El precio pagado por el consumidor final al expendedor de carne crece en mayor proporción que los precios pagados a la intermediación y al productor primario.
ABSTRACT Pork agribusiness has greatly increased at the province and national level in recent years. The productive chain includes input suppliers, farmers, animal re-sellers, abattoirs, meat packers, wholesale traders, retailers, and consumers. This study described the market agents that interact along this productive chain, and quantified the pork-marketing shares in Aburrá Valley, Antioquia province (Colombia). A convenience sampling was used in this study. A survey was applied to 30 producers and a semi-structured interview to five marketing agents. Two main marketing circuits were found: producer-meat vendor, and producer-broker-meat vendor. The prices paid to the agents that interact in the pork meat circuit in the Aburrá Valley show an upward trend. The price paid by the final consumer to the meat vendor grows in greater proportion than the prices paid to the brokers and to the primary producer.
RESUMO
OBJETIVO: Evaluar el significado pronóstico de la trombosis venosa profunda (TVP) concomitante asintomática en pacientes diagnosticados de tromboembolia de pulmón (TEP) aguda sintomática. MÉTODOS: Se realizó un análisis retrospectivo de una cohorte de 820 pacientes normotensos diagnosticados de TEP aguda sintomática incluidos en el estudio PROTECT. Se les realizó una ecografía de compresión de miembros inferiores. La variable primaria de resultado fue la mortalidad por todas las causas durante los primeros 30 días de seguimiento. La variable secundaria fue la mortalidad por TEP durante el mismo período de tiempo. RESULTADOS: De los 820 pacientes incluidos, un 46% (375) presentaron TVP. El 51% de ellos (193/375) no presentaban sintomatología sugestiva de TVP. Durante el primer mes de seguimiento fallecieron 37 pacientes (4,5%; IC 95%: 3,1-5,4%). Once pacientes de 820 fallecieron por TEP (1,3%; IC 95%: 0,6-2,1%), y 26 (26 de 820 pacientes; 3,2%; IC 95%: 2,0-4,4%) por otras causas (cáncer: 10; insuficiencia cardiaca: 4; insuficiencia respiratoria: 3; sangrado: 3, y otras causas: 6). Los pacientes con TVP asintomática presentaron un riesgo aumentado de muerte por todas las causas (odds ratio [OR] 2,77; IC 95%: 1,35-5,67; p = 0,005) y de muerte por TEP (OR 7,11; IC 95%: 1,42-35,53; p = 0,02). Ninguna de las variables analizadas modificó la asociación entre la TVP asintomática y los eventos considerados. CONCLUSIONES: En pacientes normotensos con TEP aguda sintomática, la TVP asintomática concomitante se asocia a un riesgo aumentado de muerte por todas las causas y por TEP durante el mes posterior al diagnóstico
OBJECTIVE: To evaluate the prognostic significance of concomitant asymptomatic deep vein thrombosis (DVT) in patients with symptomatic acute pulmonary embolism (PE). METHODS: A prospective study was conducted on 820 normotensive patients with PE enrolled in the PROTECT multicentre study. Ultrasound was performed on patients with bilateral lower extremity venous compression to assess for concomitant DVT. The primary study outcome, all-cause mortality, and the secondary outcome of PE-specific mortality, were assessed during the first month of follow-up after PE diagnosis. RESULTS: Of the 820 patients diagnosed with PE, 46% (375/820) had concomitant DVT, and signs or symptoms of DVT were absent in 51% (193 of 375) of these patients. Overall, 37 out of 820 patients died (4,5%; 95% confidence interval [CI], 3,1%-5,9%). Of the 820 patients, 11 (1,3%; 95% CI, 0,6%-2,1%) died from PE, and 26 (3,2%; 95% CI, 2,0%-4,4%) died from other causes (cancer: 10; congestive heart failure: 4; respiratory failure: 3; major bleeding: 3; miscellaneous diseases: 6). Patients with concomitant asymptomatic DVT had an increased all-cause mortality (odds ratio [OR] 2,77; 95% CI, 1,35-5,67;P = .005) and PE-specific mortality (OR 7,11; 95% CI, 1,42-35,53; P = ,02). None of the variables analysed affected the association between DVT and the events studied. CONCLUSIONS: In stable patients with an episode of acute symptomatic PE, the presence of concomitant asymptomatic DVT is an independent predictor of death in the ensuing month after diagnosis
Assuntos
Humanos , Masculino , Feminino , Trombose Venosa/complicações , Trombose Venosa/terapia , Embolia Pulmonar/complicações , Prognóstico , Fibrinolíticos/uso terapêutico , Estudos Retrospectivos , Extremidade Inferior/patologia , Extremidade Inferior , Cintilografia/métodos , Relação Ventilação-Perfusão/efeitos da radiação , 28599 , Estimativa de Kaplan-Meier , Intervalos de ConfiançaRESUMO
En pacientes con sintomatologia mamaria como tension premenstrual y mastodinia, observamos relacion con el empleo reciente de cremas faciales de "belleza". El estudio de estas cremas por RIA demostro en 6 de las 7 cremas estudiadas un contenido de estradiol variable, en una de las cremas fue tan alto que alcanzo 1683 pg/gr de crema. Se hace una revision somera sobre las ventajas e inconvenientes de la absorcion de estrogenos por la piel y se recomienda que el Ministerio de Sanidad tome las medidas necesarias para la proteccion del publico consumidor